Gazyva Succeeds In NOBILITY Lupus Nephritis Study But What Next?
Genentech refrained from committing to further development of its CD20 inhibitor in the indication despite meeting endpoints in Phase II study.
You may also be interested in...
Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market
The latest drug development news and highlights from our US FDA Performance Tracker.
Analysts increasingly see Roche’s pipeline and newly launched drugs winning over investors and neutralizing worries over biosimilars and potential US pricing reforms. Its 16 September pipeline update in London may reinforce that.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.